Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00926796 · ClinicalTrials.gov registry record · Phase 4

Efficacy of Combination Therapies for Gonorrhea Treatment

A Phase 4 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

Completed
Registry status
Phase 4
Development phase
614
Enrollment target

NCT00926796 is a Phase 4 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 614 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00926796, a Phase 4 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).

COMPLETED
Registry status
Phase 4
Development phase
614 participants
Enrollment target

Study Summary

The purpose of this study is to learn how to better treat gonorrhea infections. Gonorrhea is a sexually transmitted disease (STD) that is usually cured with a single antibiotic. However, some gonorrhea is not cured with a single antibiotic. The study will look at how well treating gonorrhea with 2 antibiotics works. Participants will be assigned to 1 of 2 treatment groups each receiving a combination of 2 antibiotics. Sites in the United States will recruit 500 male and female participants. Participants must be 15 to 60 years old, in good health and identified in participating sexually transmitted disease clinics as having uncomplicated cervical or urethral gonorrhea. Procedures include collection of current symptoms, medical and sexual history, sexual orientation, vital signs, height, weight, cervical/urethral cultures and clinical examinations. Volunteers will be involved for about 17 days.

Interventions

  • DRUG Azithromycin
  • DRUG Gentamicin
  • DRUG Gemifloxacin

Trial Details

FieldValue
Enrollment Target 614 participants
Start Date 2010-06
Est. Completion 2013-05
Phase Phase 4

What the Registry Record Tells You About NCT00926796

The ClinicalTrials.gov registry entry for NCT00926796 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 614 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Azithromycin is the first listed.

NCT00926796 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00926796 about?

NCT00926796 is a clinical study titled "Efficacy of Combination Therapies for Gonorrhea Treatment". The purpose of this study is to learn how to better treat gonorrhea infections. Gonorrhea is a sexually transmitted disease (STD) that is usually cured with a single antibiotic. However, some gonorrhea is not cured with a single antibiotic. The study will look at how well treating gonorrhea with 2 a...

What is the current status of trial NCT00926796?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 614 participants. The study started on 2010-06. Estimated completion is 2013-05.

What interventions are being tested in trial NCT00926796?

The interventions under investigation include: Azithromycin (DRUG), Gentamicin (DRUG), Gemifloxacin (DRUG).

Who is sponsoring clinical trial NCT00926796?

This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.